Inhibikase Therapeutics, Inc. (Nasdaq: IKT)

Potential Upside Opportunity [Image] Inhibikase Therapeutics, Inc. (NASDAQ: IKT) URGENT!! I am writing to bring your attention to Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company focused on developing treatments for neurodegenerative and infectious diseases. Its possible that IKT is poised for significant upside potential in early 2023, and here are 14 reasons why: 1. Active Chart: IKT shares had an impressive 137% move in less than a month from the beginning of 2023 to January 25th, 2023, according to price history available at Barchart.com. 2. Upside Potential: IKT shares have traded at much higher levels in the past, reaching a 2-year high of $9.16 on February 2nd, 2021. This represents a potential increase of 1,788% from its 1/3/2023 price of $.485. 3. Market Valuation: Inhibikase Therapeutics, Inc. has a market cap of around $20.29M, as of 2/23/2023, according to MarketWatch.com. 4. Low Float: Inhibikase Therapeutics, Inc. has around 19.85M shares in its float, which is considered a low float. 5. Strong Insider Ownership: Insiders own over 21% of the shares, indicating confidence in the company's prospects and ownership in its shares. 6. Innovative Pipeline: The company's innovative pipeline includes potential treatments for Parkinson's disease, Alzheimer's disease, and oncological diseases. 7. Recent FDA Decision: The company received a favorable decision from the FDA allowing the company to immediately move forward with its Phase 2a clinical trial on IkT-148009 in Parkinson's disease. 8. Encouraging Clinical Trials: Inhibikase Therapeutics, Inc. has reported encouraging results from its Phase 1 clinical trials for its lead candidate, which could potentially be used to treat Parkinson's disease with Phase 2 trials beginning in early 2023. 9. Unmet Medical Need: Neurodegenerative and infectious diseases are significant and growing public health challenges, and there is a significant unmet medical need for effective treatments. 10. Addressable Market: The market for treatments for neurodegenerative and infectious diseases is expected to be significant, providing an opportunity for Inhibikase Therapeutics, Inc. to capture a share of that market. 11. Intellectual Property: The company has a strong intellectual property portfolio, including patents on its technology and methods for treating neurodegenerative and infectious diseases. 12. Developed Novel Protein: The company has developed novel protein kinase inhibitors against c-Abl, which the company believes can alter the disease course for Parkinson's Disease. 13. Strong Partnerships: Inhibikase Therapeutics, Inc. has established strong partnerships with leading research institutions, including the National Institutes of Health (NIH) and the Michael J. Fox Foundation for Parkinson's Research. 14. Experienced Management: The company has an experienced management team with a track record of success in drug development and commercialization. Considering the aforementioned factors, its possible that Inhibikase Therapeutics, Inc. (Nasdaq: IKT) has significant potential upside in early 2023. I encourage you to conduct further research on this company and its innovative pipeline. [Click here for the full story >>]( Thank you for your time. Sincerely, Prime Tech Stocks Team Disclosure: I am not a fin-an-cial adviser. All potential percentage gains are based on from the low to the high of day. Prime Tech Stocks full disclosure is to be read and fully understood before using Prime Tech Stocks website, or joining Prime Tech Stocks’ email or text list. By viewing Prime Tech Stocks website and/or reading Prime Tech Stocks email or text newsletter you are agreeing to Prime Tech Stocks full disclosure which can be read at www (dot) primetechstocks (dot) com/disclosure/ Make sure to always do your own research and due diligence on any day and swing profile brought to your attention. Prime Tech Stocks owned by Red Oak Media Group LLC, a limited liability company. Red Oak Media Group's full disclosure document can be read at www (dot) primetechstocks (dot) com/disclosure/ We do not own any shares in IKT. We have been compensated up to Eight Thousand Three Hundred and Thirty Three Dollars via bank wire transfer from a third-party TD Media LLC for a 3 Day Marketing Program regarding IKT with a start date of 3/29/2023 to 3/31/2023. Red Oak Media Group LLC, 7940 Ann Arbor St Dexter MI USA 48130 To update contact information or unsubscribe from this list, please [click here](